natgillin/translations-raw huggingface dataset:
Tilfælde af egentlig hypoglykæmi risikerer endvidere ikke at blive behandlet, hvis den hypoglykæmiske tilstand skjules af falsk forhøjede glukoseaflæsninger. 
Also, cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings.
- Hos personer, der ikke har udvist immunrespons (ingen målbare hepatitis B-antistoffer) efter vaccination, og som har brug for kontinuerlig forebyggelse på grund af den fortsatte risiko for infektion med hepatitis B. 
- In subjects who did not show an immune response (no measurable hepatitis B antibodies) after vaccination and for whom a continuous prevention is necessary due to the continuous risk of being infected with hepatitis B.
Ét hætteglas på 1 ml indeholder 312 IE anti-HB-antistoffer. 
One vial of 1 ml contains 312 IU of anti-HBs.
De anvendte forholdsregler har muligvis begrænset virkning på ikke-indkapslede virus som HAV og parvovirus B19. 
The measures taken may be of limited value against non-enveloped viruses such as HAV and parvovirus B19.
- Spørg lægen eller sundhedspersonalet, hvis der er mere, du vil vide. 
- If you have any further questions, ask your doctor.
ImmunoGam er en klar til let opaliserende og farveløs eller svagt gul opløsning. 
ImmunoGam is a clear to slightly opalescent and colourless or pale yellow liquid.
- hvis du lider af IgA-mangel, så du har udviklet allergiske reaktioner over for medicin, der indeholder IgA. 
- if you have an IgA deficiency such that you have developed an allergic reaction to IgA containing products
Ét hætteglas på 5 ml indeholder 1560 IE anti-HB-antistoffer. 
One vial of 5 ml contains 1560 IU of anti-HBs.
Ét hætteglas indeholder 312 IE anti-HB-antistoffer i 1 ml opløsning Ét hætteglas indeholder 1.560 IE anti-HB-antistoffer i 5 ml opløsning 
One vial contains 312 IU of anti-HBs in 1 ml One vial contains 1560 IU of anti-HBs in 5 ml
Hvis det er nødvendigt med samtidig vaccination, skal immunglobulin og vaccinen indsprøjtes på to forskellige 
When simultaneous vaccination is necessary, the immunoglobulin and the vaccine should be administered at two
Dette kan give falsk forhøjede glukoseaflæsninger og medføre fejlagtig indgivelse af insulin, hvilket kan resultere i livstruende hypoglykæmi. 
This may result in falsely elevated glucose readings and consequently in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia.
I sjældne tilfælde kan humant hepatitis B-immunglobulin medføre blodtryksfald med anafylaktiske reaktioner, også hos patienter, der har tålt tidligere behandlinger med immunglobulin. 
Rarely, human hepatitis B immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who have tolerated previous treatment with immunoglobulin.
Det anbefales på det kraftigste at vaccinere mod hepatitis B-virus. 
Vaccination against hepatitis B virus is highly recommended.
Opløsningen skal være klar eller let opaliserende og farveløs eller svagt gul. 
The solution should be clear to slightly opalescent and colourless or pale yellow.
Kliniske erfaringer med immunglobuliner tyder på, at der ikke kan forventes skadelige påvirkninger af graviditetens 
Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the fetus and the neonate are to be expected.
Ved indsprøjtning af ImmunoGam i en muskel viser overdosering sig kun som smerter og ømhed på indsprøjtningsstedet. 
For intramuscular administration of ImmunoGam, the only manifestations of overdose would be pain and tenderness at the injection site.
• Generelt kan immunglobuliner give bivirkninger såsom kuldegysninger, hovedpine, feber, opkastning, allergiske reaktioner, kvalme, ledsmerter (artralgi), lavt blodtryk og moderate lændesmerter. 
• Immunoglobulins in general may cause adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia (joint pain), low blood pressure and moderate low back pain.
Blod- og plasmadonorerne udvælges omhyggeligt for at udelukke donorer, der kan være bærere af infektioner, og hver enkelt portion blod og puljet plasma undersøges for at se, om den indeholder tegn på virus eller infektioner. 
These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/infections.
- Hos patienter, der er i behandling med hæmodialyse, indtil vaccinationen virker. 
- In haemodialysed patients, until vaccination has become effective.
Ikke anvendte lægemidler bør destrueres i henhold til lokale retningslinjer. 
Any unused product should be disposed of in accordance with local requirements.
Det anbefales på det kraftigste, at lægemidlets navn og batchnummer registreres hos din læge, hver gang du får indsprøjtet en dosis ImmunoGam, så det vides, hvilke batch du har fået. 
It is strongly recommended that every time you receive a dose of ImmunoGam, the name and batch number of the product are recorded in your physician's notes in order to maintain a record of the batches used.
Patienter med stærkt nedsat antal blodplader (trombocytopeni) eller koagulationsproblemer må normalt ikke få intramuskulære indsprøjtninger og må derfor kun få ImmunoGam, hvis de forventede fordele opvejer den potentielle risiko. 
In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, ImmunoGam should be given only if the expected benefits outweigh the
Indgivelse af hepatitis B-immunglobulin skal muligvis gentages, til der konstateres 
The hepatitis B immunoglobulin administration may need to be repeated until
MINDSTEKRAV TIL MÆRKNING, DER SKAL ANFØRES PÅ SMÅ INDRE EMBALLAGER ETIKET PÅ HÆTTEGLAS 
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Ikke almindelig (≥1/1.000 til <1/100) Ikke almindelig (≥1/1.000 til <1/100) Ikke almindelig (≥1/1.000 til <1/100) Ikke almindelig (≥1/1.000 til <1/100) 
Uncommon (≥1/1,000 to <1/100) Uncommon (≥1/1,000 to <1/100) Uncommon (≥1/1,000 to <1/100)
ImmunoGam er en injektionsvæske, der fås som en opløsning i et hætteglas. 
ImmunoGam is presented as a solution for injection in a glass vial.
Hver ml indeholder 312 IE/ml humant hepatitis B-immunglobulin svarende til et proteinindhold på 30-70 mg/ml, hvoraf mindst 96 % er immunglobulin G (IgG). 
Each ml contains 312 IU Human Hepatitis B Immunoglobulin corresponding to a protein content of 30-70 mg/ml with at least 96% Immunoglobulin G (IgG).
Blodsukkermåling: Når der indgives ImmunoGam, skal blodsukkeret måles med en metode, der kan genkende glukose. 
Blood glucose testing: when administering ImmunoGam, the measurement of blood glucose must be done with a glucose-specific method.
Den første vaccinedosis kan indgives på samme dag som humant hepatitis B-immunglobulin, men der skal anvendes forskellige 
The first vaccine dose can be injected on the same day as human hepatitis B immunoglobulin, however in different sites.
Se pkt. 
oC).
- Patienter, der er i behandling med bloddialyse, indtil vaccinationen virker. 
- Haemodialysed patients, until vaccination has become effective.
Dette skyldes, at ImmunoGam kan påvirke din reaktion på visse vacciner med levende svækket virus mod f.eks. fåresyge, røde hunde, mæslinger og skoldkopper. 
This is because ImmunoGam may interfere with the response to some attenuated vaccines, such as measles, rubella, mumps, and chicken pox.
Hvis indgivelse af humant hepatitis B-immunglobulin er nødvendig inden for tre til fire uger efter vaccinationen, skal der foretages revaccination tre måneder efter indgivelse af humant hepatitis B 
Human hepatitis B immunoglobulin should be administrated three to four weeks after vaccination with such a live attenuated vaccine; in case administration of human hepatitis B immunoglobulin is essential within three to four weeks after vaccination, then revaccination should be performed three months after the administration of
Der er ikke rapporteret om bivirkninger ved brug af ImmunoGam til indikationer for immunprofylakse mod 
No adverse events were reported in the post marketing use of ImmunoGam for Immunoprophylaxis of
Forholdsreglerne har muligvis begrænset virkning på ikke-indkapslede virus som hepatitis A-virus og den såkaldte parvovirus B19. 
The measures taken may be of limited value against non-enveloped viruses such as hepatitis A virus and parvovirus B19.
• Fortæl det altid til lægen eller på apoteket, hvis du bruger anden medicin eller har brugt det for nylig. 
• Please tell your doctor or nurse, if you are taking or have recently taken any other medicines, including medicines obtained without a prescription e.g. herbal medicines.
Under behandlingen af blodet eller plasmaet sørger fremstillerne af denne type lægemidler desuden for at inaktivere eller fjerne virus. 
Manufacturers of these products also include steps in the processing of the blood or plasma that can inactivate or remove viruses.
På grund af risikoen for chok skal det kontrolleres, at ImmunoGam ikke indgives i et blodkar. 
Ensure that ImmunoGam is not administered into a blood vessel, because of the risk of shock.
DET SKAL DU VIDE, FØR DU BEGYNDER AT BRUGE IMMUNOGAM 
BEFORE YOU RECEIVE IMMUNOGAM
Bivirkninger som kuldegysninger, hovedpine, feber, opkastning, allergiske reaktioner, kvalme, artralgi, lavt blodtryk og moderate lændesmerter kan generelt forekomme periodisk i forbindelse med immunglobulinprodukter. 
In general for immunoglobulin products, adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Nedenstående tabel viser de bivirkninger, der er forbundet med lægemidlet og opstået inden for 7 dage efter indgivelse af ImmunoGam og er konstateret i forbindelse med kliniske forsøg med intramuskulær indgivelse: 
Related undesirable effects within 7 days of ImmunoGam administration, from clinical trials conducted using the intramuscular route of administration is tabulated below:
4.4 vedrørende sikkerhed i forbindelse med overførsel af smitstoffer. 
For safety with respect to transmissible agents, see section 4.4
ImmunoGam bør have stuetemperatur (ca. 20 ºC - 25ºC) før brug. 
ImmunoGam should be brought to room temperature (approximately 20 ºC to 25ºC) before use.
- Hos personer, der ikke er vaccineret, og som ved et uheld bliver udsat for smitte (inklusive personer, hvor vaccinationen endnu ikke er komplet, eller hvor det ikke vides, om den er komplet). 
- Accidental exposure in non-immunised subjects (including persons whose vaccination is incomplete or
De fleste af disse er immunglobulin G (IgG), som er taget fra blodplasma fra omhyggeligt 
ImmunoGam contains increased levels of human hepatitis B immunoglobulins mainly immunoglobulin G (IgG) and is obtained from blood plasma of screened donors from
Hver 2. måned, til der konstateres en virkning (serokonvertering efter vaccination) Indgivelse af hepatitis B-immunglobulin skal muligvis gentages, til der konstateres serokonvertering efter vaccination 
The hepatitis B immunoglobulin administration may need to be repeated until seroconversion following vaccination
På trods af disse forholdsregler kan muligheden for overførsel af infektioner ikke helt udelukkes, når der indsprøjtes lægemidler fremstillet af blod eller plasma fra mennesker. 
Despite these measures, when medicines prepared from human blood or plasma are administered the possibility of passing on infection cannot be totally excluded.
Denne forholdsregel betragtes som effektive for indkapslede virus som HIV (human immundefektvirus), 
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus.
- Personer, der er blevet vaccineret, men ikke reagerer på vaccinen (ikke har målbare hepatitis B-antistoffer i blodet), og som har brug for fortsat forebyggelse, fordi de stadig har risiko for at blive smittet med 
- Subjects who did not show an immune response (no measurable hepatitis B antibodies) after vaccination and for whom a continuous prevention is necessary due to the continuous risk of being infected with
- Hos nyfødte, hvor moderen er bærer af hepatitis B-virus. 
- In the newborn of a hepatitis B virus carrier-mother.
- Nyfødte, hvor moderen er bærer af hepatitis B-virus. 
- Newborn of a hepatitis B virus carrier-mother.
Hvis du har brugt for meget ImmunoGam 
If more ImmunoGam is used than recommended
ImmunoGam fås i hætteglas med 1 ml eller 5 ml, der indeholder 30-70 mg humant plasmaprotein pr. milliliter. 
ImmunoGam comes in a 1 ml or 5 ml vial containing 30-70 mg/ml of human plasma protein of which 96% (312 IU/ml) is Immunoglobulin G (IgG).
På trods af dette kan muligheden for overførsel af infektionskilder ikke helt udelukkes ved indgivelse af lægemidler fremstillet af humant blod eller plasma. 
Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded.
Afhængigt af eksponeringsintensiteten snarest muligt efter eksponering og helst inden for 
At least 500 IU depending on the intensity of exposure, as soon as possible after exposure, and preferably within 24 - 72 hours every 2 months until seroconversion following
Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne. 
Hypersensitivity to any of the components.
Dette kan igen betyde, at der fejlagtigt ordineres insulin, hvilket kan resultere i for lavt blodsukker (hypoglykæmi). 
This may result in falsely elevated glucose readings and consequently in the inappropriate administration of insulin which may result in hypoglycemia.
ImmunoGam kan medføre en stigning i antallet af forskellige overførte antistoffer. 
ImmunoGam may cause a rise of various transferred antibodies which may result in misleading positive results of certain blood serum tests.
Tal med lægen eller apoteket, hvis en bivirkning er generende eller bliver værre, eller du får bivirkninger, som ikke er nævnt her. 
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
Immunglobuliner er ikke sat i forbindelse med infektioner med hepatitis A eller parvovirus B19. 
Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective.
Der skal tages hensyn til øvrige officielle retningslinjer for dosering og doseringsplaner ved intramuskulær 
Consideration should also be given to dose and dose schedules for human hepatitis B immunoglobulin for intramuscular use recommended in other official guidance.
Bulgarien Tchaikapharma High Quality Medicines, Inc. 
Tchaikapharma High Quality Medicines, Inc.
ORAL ANVENDELSE 
ORAL USE
Danmark Strides Arcolab International Limited 
Strides Arcolab International Limited
Spanien Accord Healthcare S.L.U. 
Accord Healthcare S.L.U.
Belgien Mylan Bvba-Sprl 
Mylan Bvba-Sprl
Ungarn Fresenius Kabi Hungary Kft. 
Fresenius Kabi Hungary Kft.
KAPSEL 
CAPSULE
PULVER TIL KONCENTRAT TIL 
POWDER FOR CONCENTRATE FOR
Kroatien Pliva Hrvatska D.O.O. 
Pliva Hrvatska D.O.O.
Slovenien Pfizer Luxembourg Sarl 
Pfizer Luxembourg Sarl
Grækenland Pharmaserve-Lilly Saci 
Pharmaserve-Lilly Saci
Holland Pharma Regulatory Solutions Ltd. 
Pharma Regulatory Solutions Ltd.
Spanien Laboratorio Ramon Sala, S.L 
Laboratorio Ramon Sala, S.L
Tyskland Hexal Ag 
Hexal Ag
Grækenland Demo Abee 
Demo Abee
Rumænien Pharmaswiss česká Republika S.R.O. 
Pharmaswiss česká Republika S.R.O.
Litauen Teva Pharma B.V. 
Teva Pharma B.V.
Holland Fresenius Kabi Nederland B.V. 
Fresenius Kabi Nederland B.V.
Grækenland Vianex S.A. 
Vianex S.A.
Rumænien Fresenius Kabi Romania S.R.L. 
Fresenius Kabi Romania S.R.L.
Spanien Pfizer, S.L. 
Pfizer, S.L.
Tyskland Dr. Friedrich Eberth Arzneimittel Gmbh 
Dr. Friedrich Eberth Arzneimittel Gmbh
Cypern Pharmaceutical Trading Co Ltd 
Pharmaceutical Trading Co Ltd
Belgien Teva Pharma Belgium N.V.-S.A 
Teva Pharma Belgium N.V.-S.A
Spanien Mylan Pharmaceuticals, S.L. 
Mylan Pharmaceuticals, S.L.
Frankrig Fresenius Kabi France S.A.S. 
Fresenius Kabi France S.A.S.
Holland Mylan B.V. 
Mylan B.V.
Holland Eurocept B.V. 
Eurocept B.V.
Spanien Kern Pharma, S.L. 
Kern Pharma, S.L.
Luxembourg Sandoz N.V. 
Sandoz N.V.
Spanien Fresenius Kabi España S.A.U. 
Fresenius Kabi España S.A.U.
Kroatien Pharmaswiss D.O.O. 
Pharmaswiss D.O.O.
Indústria Farmacêutica, S.A. 
Generis Farmacêutica, S.A.
Cypern Sapiens Pharmaceuticals Ltd 
Sapiens Pharmaceuticals Ltd
KAPSEL, HÅRD 
CAPSULE, HARD ORAL USE
Holland Sandoz B.V. 
Sandoz B.V.
Holland Pfizer B.V. 
Pfizer B.V.
Kroatien Sandoz D.O.O. 
Sandoz D.O.O.
Anfarm Hellas, S.A 
Anfarm Hellas, S.A Vangrotin
Pharmatex Italia Srl 
Pharmatex Italia Srl Vancotex
INHALATION 
INHALATION USE
Det Forenede Flynn Pharma Ltd. 
United Kingdom Flynn Pharma Ltd.
Laboratórios AzevedosIndústria Farmacêutica, S.A. 
Laboratórios Azevedos - Indústria Farmacêutica, S.A.
Grækenland Finixfarm Ltd 
Finixfarm Ltd
Tyskland Fresenius Kabi Deutschland Gmbh 
Fresenius Kabi Deutschland Gmbh
PULVER TIL ORAL 
POWDER FOR ORAL SOLUTION
Kroatien Fresenius Kabi D.O.O. 
Fresenius Kabi D.O.O.
Accord Healthcare Limited Vancomicina Combino 
Accord Healthcare Limited
VANCOMYCINHYDROCHLORID 1025 MG/1025 MG 
VANCOMYCIN HYDROCHLORIDE 1025MG/1025 MG
Vancotex 
Levovanox
S.A 
G
Mcdermott Laboratories Ltd Vancomycin Mylan 
Mcdermott Laboratories Ltd
Vancomycin Wockhardt Uk Ltd 
Wockhardt Uk Ltd Vancomycin Wockhardt Uk Ltd
Enterprises Ltd. 
Noridem Enterprises Ltd
Laboratorio Reig Jofre, S.A. Vancomycin Laboratorio 
United Kingdom Laboratorio Reig Jofre, S.A.
Tyskland Lyomark Pharma Gmbh Vancomycin Lyomark 
Lyomark Pharma Vancomycin Lyomark VANCOMYCIN
VANCOMYCINHYDROCHLORID 512,5 MG/512,5 MG 
VANCOMYCIN HYDROCHLORIDE 512.5MG/512.5 MG
VANCOMYCINHYDROCHLORID 128,15 MG KAPSEL 
VANCOMYCIN HYDROCHLORIDE 128.15MG CAPSULE
PULVER TIL ORAL OPLØSNING, PULVER 
POWDER FOR ORAL SOLUTION, POWDER
Enterprises 
Trading
VANCOMYCINHYDROCHLORID 1000 MG/1000 MG 
VANCOMYCIN HYDROCHLORIDE 1000MG/1000 MG
Generics [uk] Limited Vancomycin Mylan 
Generics [uk] Limited Vancomycin Mylan VANCOMYCIN 1000MG VIAL
PULVER TIL INJEKTIONSVÆSKE 
POWDER FOR INJECTION
Vancomycin Hydrochloride Pharmaceutical Trading 
Vancomycin Hydrochloride Pharmaceutical
PULVER TIL INFUSIONSVÆSKE, OPLØSNING / PULVER TIL ORAL OPLØSNING 
POWDER FOR SOLUTION FOR INFUSION / POWDER FOR ORAL SOLUTION
Vancomycine Pfizer 
Vancomycine Pfizer VANCOMYCIN
VANCOMYCINHYDROCHLORID 512,57 MG/10 ML 
VANCOMYCIN HYDROCHLORIDE 512.57MG/10 ML
VANCOMYCIN 1000 MG/20 ML 
Vancomycine Teva VANCOMYCIN 1000MG/20 ML
VANCOMYCINHYDROCHLORID 500 MG/500 MG 
VANCOMYCIN HYDROCHLORIDE 500MG/500 MG
VANCOMYCIN 1000 MG PULVER TIL 
VANCOMYCIN 500MG POWDER FOR
Holland Hospira Benelux Bvba Vancomycin Hospira 
Hospira Benelux Vancomycin Hospira VANCOMYCIN
VANCOMYCINHYDROCHLORID 512,571 MG ENHEDER 
VANCOMYCIN HYDROCHLORIDE 512.571MG UNITS
Tyskland Ratiopharm Gmbh 
Ratiopharm Gmbh Vanco
Hospira Deutschland Gmbh Vanycin 
Hospira Deutschland Gmbh
Tyskland Fresenius Kabi Deutschland Vancomycin VANCOMYCIN 500 MG PULVER TIL 
Fresenius Kabi ванкомицин каби VANCOMYCIN 500MG POWDER FOR
VANCOMYCINHYDROCHLORID 0,5 G FLASKE 
VANCOMYCIN HYDROCHLORIDE 0.5G BOTTLE
ORAL OPLØSNING, PULVER TIL 
ORAL SOLUTION, POWDER FOR INFUSION
Vancomycin VANCOMYCINHYDROCHLORID 1 G FLASKE 
VANCOMYCIN HYDROCHLORIDE 1G BOTTLE
VANCOMYCINHYDROCHLORID 50 MG/ML 
HYDROCHLORIDE 50MG/ML
Vancomicina CNP 
Vancocin Cp
VANCOMYCIN 125 MG KAPSEL 
VANCOMYCIN 125MG CAPSULE
Tyskland Hikma Farmacêutica (Portugal), S.A. 
United Kingdom Hikma Farmacêutica (Portugal), S.A.
Holland Hikma Farmacêutica (Portugal), S.A. 
Vancomycin Hikma Farmacêutica (Portugal), S.A.
Morningside Healthcare Ltd Vancomycin Morningside 
Vancomycin Morningside Healthcare
Slovenien FarmaPlus AS 
FarmaPlus AS
VANCOMYCINHYDROCHLORID 1000 MG 
VANCOMYCIN HYDROCHLORIDE 1000MG
INFUSIONSVÆSKE 
INFUSION
Pfizer Healthcare Ireland Vancomycin Pfizer 
Vancomycin Pfizer Healthcare Ireland
VANCOMYCINHYDROCHLORID 1000 MG FLASKE 
VANCOMYCIN HYDROCHLORIDE 1000 mg bottle
Vanmicira 
Vanycin
Grækenland Fresenius Kabi Hellas A.E. Vancomycin Kabi 
Fresenius Kabi Hellas A.E.
PULVER TIL ORAL OPLØSNING, PULVER TIL INFUSIONSVÆSKE, 
POWDER FOR ORAL SOLUTION, POWDER FOR SOLUTION FOR INJECTION
Ungarn Pharmacologic Kft 
Pharmacologic Kft Vancocin
PULVER TIL INJEKTIONS/INFUSION-VÆSKE, OPLØSNING 
SOLUTION FOR INJECTION/INFUSION
Vancomycin Mip VANCOMYCIN 1000 MG HÆTTEGLAS 
Vancomycin Mip VANCOMYCIN 1000MG VIAL
Tyskland Actavis Group Ptc Ehf. 
United Kingdom Actavis Group Ptc Ehf.
Litauen Mip Pharma Gmbh 
Lyomark Pharma Gmbh
VANCOMYCINHYDROCHLORID 10252 MG ENHEDER 
VANCOMYCIN HYDROCHLORIDE 1025.2MG UNITS
VANCOMYCIN 250 MG KAPSEL 
Vancomycin Enterocaps 250 Mg Kapseln
Bulgarien Mip Pharma Gmbh ванкомицин Mip 
Mip Pharma Gmbh Vancomycin Mip Pharma
Vancocin Cp VANCOMYCIN 500 MG OG 1000 MG 
Vancomycin Hospira VANCOMYCIN 1000MG and 500 MG VIAL
Pharmacodane Aps 
Pharmacodane Aps Vancocin
VANCOMYCINHYDROCHLORID 500 MG 
VANCOMYCIN HYDROCHLORIDE 500MG
1000 MG HÆTTEGLAS 
1000 mg VIAL
Bulgarien Fresenius Kabi Bulgaria Eood ванкомицин каби 
Fresenius Kabi Bulgaria Eood ванкомицин каби VANCOMYCIN 1000MG VIAL
Fresenius Kabi Limited Vancomycin Fresenius Kabi 
Fresenius Kabi Nv-Sa Vancomycine Fresenius Kabi
Grækenland Generics Pharma Hellas Ltd Vancomycin Generics 
Generics Pharma Hellas Ltd
Fresenius Kabi Norge As Vancomycin Fresenius Kabi 
Fresenius Kabi Ab Vancomycin Fresenius Kabi
Mip Pharma Austria Gmbh Vancomycin Mip VANCOMYCIN 1000 MG HÆTTEGLAS 
Mip Pharma Gmbh Vancomycin Mip VANCOMYCIN 1000MG VIAL
Mip Pharma Austria Gmbh Vancomycin Mip VANCOMYCIN 500 MG HÆTTEGLAS 
Mip Pharma Gmbh Vancomycin Mip VANCOMYCIN 500MG VIAL
Hospira Uk Ltd 
Hospira Uk Ltd Vanmicira
Ungarn Teva Gyógyszergyár Zrt VancomycinHuman Teva 
Vancomycin-Human Teva Gyógyszergyár
Belgien Hospira Benelux Bvba Vancomycin Hospira 
Hospira Benelux Bvba
Vancomycin Mip VANCOMYCIN 500 MG HÆTTEGLAS 
Vancomycin Mip VANCOMYCIN 500MG VIAL
VANCOMYCIN 1000 MG OG 500 MG HÆTTEGLAS 
VANCOMYCIN 500MG and 1000MG
Vancomicina VANCOMYCINHYDROCHLORID 1025,14 MG HÆTTEGLAS 
VANCOMYCIN HYDROCHLORIDE 1025.14MG VIAL
PULVER TIL INFUSION INTRAVENØS ANVENDELSE 
POWDER FOR INFUSION
Noridem Enterprises Ltd Vancomycin Noridem 
Vancomycin Noridem Enterprises Ltd.
Bulgarien Hospira Uk Ltd ванкомицин хоспира 
United Kingdom Hospira Uk Ltd Vancomycin Hydrochloride
Actavis 
аквисцин
Cnp Pharma Gmbh 
Cnp Pharma Gmbh Vancosan
Vancocin VANCOMYCINHYDROCHLORID 250 MG KAPSEL 
VANCOMYCIN HYDROCHLORIDE 250MG CAPSULE
Vancocin VANCOMYCIN 125 MG KAPSEL 
Vancomycin Actavis VANCOMYCIN 125MG CAPSULE
VANCOMYCINHYDROCHLORID 256 MG KAPSEL 
VANCOMYCIN HYDROCHLORIDE 256MG CAPSULE
Tyskland Hospira Deutschland Gmbh Vancomycin Hospira 
Hospira Portugal Lda Vancomycin Hospira VANCOMYCIN HYDROCHLORIDE
Vancomycin VANCOMYCINHYDROCHLORID 500 MG FLASKE 
VANCOMYCIN HYDROCHLORIDE 500MG BOTTLE
Vancomycin Hydrochloride Hospira 
Vancomycin Hospira VANCOMYCIN HYDROCHLORIDE
Vangrotin VANCOMYCINHYDROCHLORID 500 HÆTTEGLAS 
Vancomycin hydrochloride 500 Vial
Vancocin VANCOMYCIN 1 G 
Vancomycine Teva VANCOMYCIN HYDROCHLORIDE 1G
INFUSIONSVÆSKE, 
DIRECT INTRAVENOUS INJECTION
Det Forenede Xellia Pharmaceuticals Aps Vancomycin VANCOMYCIN 125 MG KAPSEL 
Vancomycin Xellia VANCOMYCIN 125MG CAPSULE
Vancocin Cp VANCOMYCIN 250 MG KAPSEL 
Vancomycin Actavis VANCOMYCIN 250MG CAPSULE
Kabi 
Bvba
VANCOMYCINHYDROCHLORID 500 MG FLASKE 
VANCOMYCIN Hydrochloride 500MG bottle
Vancocin VANCOMYCINHYDROCHLORID 125 MG KAPSEL 
VANCOMYCIN HYDROCHLORIDE 125MG CAPSULE
Finland Mip Pharma Gmbh 
Mip Pharma Austria Gmbh
512,57 MG HÆTTEGLAS INFUSIONSVÆSKE, OPLØSNING 
1025.14MG VIAL FOR SOLUTION FOR INFUSION
Letland Pfizer Europe Ma Eeig Vancomycin Pfizer 
Pfizer Europe Ma Eeig Vancomycin Pfizer VANCOMYCIN 500MG VIAL
Vancocin Cp VANCOMYCINHYDROCHLORID 1 G AMPUL 
Vancomycin Mylan VANCOMYCIN HYDROCHLORIDE 1G BOTTLE
Vancomycin CoPharma 
United Kingdom Co-Pharma Limited Vancomycin CoPharma
Vancomycin Cnp Pharma 
Cnp Pharma Gmbh Vancomycin Cnp Pharma
VANCOMYCINHYDROCHLORID 1 G 
VANCOMYCIN HYDROCHLORIDE 1G VIAL
OPLØSNING, PULVER TIL INFUSIONSVÆSKE, OPLØSNING 
SOLUTION, POWDER FOR SOLUTION FOR INJECTION